bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
303 hedge funds and large institutions have $9B invested in bluebird bio in 2018 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 93 increasing their positions, 113 reducing their positions, and 44 closing their positions.
27% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 44
10% more call options, than puts
Call options by funds: $185M | Put options by funds: $168M
2% more funds holding
Funds holding: 296 → 303 (+7)
0.06% less ownership
Funds ownership: 8.21% → 8.14% (-0.06%)
3% less capital invested
Capital invested by funds: $9.26B → $9B (-$260M)
18% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 113
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$200M |
| 2 |
Goldman Sachs
New York
|
+$74.2M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$65.4M |
| 4 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$57.4M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$53.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$60.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$60M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$51M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$48.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$47.3M |
BLUE Hedge Fund Activity: Q1 2018 in Review
303 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2018, worth a combined $9B — down 2.8% from $9.26B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new BLUE positions and 44 closed out — a net gain of 12 holders — while 93 added to existing stakes and 113 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $200M. The largest seller was Wellington Management Group, cutting an estimated $60.9M.
- 303 institutional investors held bluebird bio (BLUE) as of Q1 2018, up from 296 in Q4 2017.
- Funds reported $9B of bluebird bio stock for Q1 2018, down 2.8% quarter-over-quarter.
- 56 funds opened new bluebird bio positions in Q1 2018 and 44 closed out, a net change of +12 holders.
- The largest bluebird bio buyer in Q1 2018 was Capital International Investors, an estimated $200M added.
- The largest bluebird bio seller in Q1 2018 was Wellington Management Group, an estimated $60.9M sold.
Based on aggregated 13F filings for Q1 2018.